[pubmed] Chronic immunoglobulin maintenance therapy in myasthenia gravis
Posté : 23 sept. 2020 12:00
Eur J Neurol. 2020 Sep 22. doi: 10.1111/ene.14547. Online ahead of print.
ABSTRACT
BACKGROUND: Long-term treatment of myasthenia gravis (MG) includes symptomatic and course-modifying therapies that target the immune system. Recently, both IVIG and subcutaneous immunoglobulin (SCIG) have emerged as viable options for chronic therapy, considering the favourable safety-efficacy profile and possible immunosuppressant sparing properties. We aimed to investigate the outcomes of the long term care of generalized MG with immunoglobulins (Ig).
METHODS: This is a retrospective, repeated-measures design study. We analyzed charts of generalized MG (gMG) patients, treated with IVIG/SCIG for at least 6 months, from January 2015 to January 2020. The primary outcome was the mean change in Myasthenia Gravis Impairment Index (MGII) after treatment with Ig, comparing baseline to IVIG and SCIG treatment periods. Secondary outcomes included the changes in pyridostigmine, immunosuppressive medications and patient-reported outcome "percentage of normal" (%N) (0-100%).
RESULTS: Thirty-four patients were treated with chronic Ig therapy (30 IVIG/SCIG, 3 SCIG, 1 IVIG). Mean duration of IVIG and SCIG periods were 21.8±19.4 (range 3-64) and 19.5±11.3 (range 5-45) months respectively. There was a significant reduction in MGII scores (27.7±15.7 baseline; 22.0±17.4 IVIG period;19.5±18.1 SCIG period;F=17.9; df =1.7;p
Source: https://pubmed.ncbi.nlm.nih.gov/3296456 ... 8&v=2.11.5